Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104020 | 1.00 | POLB (0.40) | POLBABCC4MAPTALDH1A1KMT2A | |
| SCHEMBL10303857 | 0.87 | POLB (0.43) | POLBABCC4MAPTALDH1A1KMT2A | |
| SCHEMBL17121284 | 0.82 | POLB (0.41) | POLBABCC4MAPTALDH1A1KMT2A | |
| SCHEMBL12951832 | 0.82 | DDAH1 (0.33) | POLBABCC4MAPTALDH1A1LMNA | |
| SCHEMBL3588661 | 0.81 | EPHX2 (0.32) | ABCC4MAPTEPHX2 | |
| SCHEMBL7687818 | 0.80 | POLB (0.37) | POLBALDH1A1KMT2ADDAH1 | |
| SCHEMBL14850987 | 0.80 | POLB (0.35) | POLBABCC4MAPTALDH1A1KMT2A | |
| SCHEMBL10303835 | 0.76 | EPHX2 (0.34) | ALDH1A1LMNAEPHX2NAAA | |
| SCHEMBL19215358 | 0.75 | ALDH1A1 (0.42) | POLBABCC4MAPTALDH1A1KMT2A | |
| SCHEMBL14548729 | 0.74 | POLB (0.47) | POLBABCC4MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2111396-B1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | JANSSEN R & D IRELAND (IE) | 2013-08-07 | — | — | EP | disclosed |
| US-8383584-B2 | HCV inhibiting macrocyclic phenylcarbamates | MEDIVIR AB (SE) | 2013-02-26 | — | — | US | disclosed |
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | MEDIVIR AB | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | COPB1, HAVCR2, NOD1 | POLB 445/4885ABCC4 1256/4885MAPT 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.